Brain MRI checks every 6 months for people with stage IV breast cancer
Official title: Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
Run by H. Lee Moffitt Cancer Center and Research Institute · NCT07357298 · Data updated 2026-11-12
This phase III trial tests whether routine brain MRI every six months helps detect brain metastases earlier in adults with stage IV breast cancer who have no brain symptoms.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 156 (estimated) |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute Academic / other |
| Locations | 2 sites (Miami, Florida and 1 other locations) |
| Status | Recruiting |
| Started | February 25, 2026 |
| Main results expected | February 2030 |
| Study ends | February 2030 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT07357298 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with histologically confirmed breast cancer that is stage IV with known ER/PR/HER2 status and measurable extracranial disease, who are starting or recently started first- or second-line systemic therapy and are fit for MRI.
✕Probably not a fit
Patients with brain metastases at baseline, leptomeningeal disease, or those unlikely to benefit from earlier detection may not experience improved outcomes.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this randomized, multi‑center study, patients are assigned 1:1 to scheduled brain MRI surveillance every six months or to imaging only when symptoms appear. Participants are stratified by receptor subtype, age, prior therapy, and site before randomization. The goal is to see if earlier detection changes treatment choices, brain metastasis frequency, occurrence of leptomeningeal disease, quality of life, and survival. Brain imaging uses standard surveillance MRI versus standard-of-care imaging triggered by symptoms. The study is led by H. Lee Moffitt Cancer Center with regional collaborators and sites in Florida.
Why it matters
Potential benefit: If successful, routine surveillance MRI could lead to earlier detection and potentially more effective treatment of brain metastases.
How similar studies have gone: Prior studies in brain metastases testing strategies have shown mixed results; this trial tests a targeted surveillance approach in a well-defined population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status * Radiographic evidence of stage IV extracranial disease enrolled within 60 days of diagnosis or starting first line therapy. HR+/HER2- patients may be enrolled within 60 days of starting 2nd line therapy as well. * HR+ will be defined as ER and/or PR \> 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines41. Triple negative will be classified as ER and PR \<10% and HER2-. * Age ≥ 18 * Life expectancy ≥ 6 months * Eastern Cooperative Oncology Group performance status ≤ 2 * Patients must be able to understand and the willingness to sign an informed consent for study procedures * Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Prior diagnosis or treatment of brain metastases or leptomeningeal disease * History of other non-breast malignancy requiring treatment with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of \> 90%), such as but not limited to, non-melanoma skin cancers, stage I endometrioid uterine cancer, and others at the discretion of the PI * Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment * Indications warranting brain MRI for other neurologic conditions at time of study entry (including multiple sclerosis, stroke, traumatic brain injuries, epilepsy, hydrocephalus and pituitary gland disorders) * Contraindication towards MRI with contrast * Chronic kidney disease stage IV or V or end stage renal disease (CrCl \<30 ml/min)
Where it's running
-
Moffitt Cancer Center
Tampa, Florida, United States Recruiting -
Baptist Health South Florida
Miami, Florida, United States Not yet recruiting
Study contacts
- Principal investigator: Kamran Ahmed, MD — Moffitt Cancer Center
- Study coordinator: Rheese McNab
- Email: Rheese.McNab@moffitt.org
- Phone: 813-745-1780
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.